More protests are expected in Memphis following the release of a video showing police brutally beating Tyre Nichols, whose family will be holding a funeral for him on Wednesday. Plus, the matchup for Super Bowl 57 is all set, and what to know about "Ozempic face," a side effect of the diabetes drug that's growing in popularity for weight loss. |
|
|
Another round of protests is expected tonight in Memphis, three days after video showing five ex-Memphis police officers brutally beating Tyre Nichols following a traffic stop. Nichols, 29, died three days later after being hospitalized. The Memphis police announced they have permanently deactivated its Scorpion anti-crime unit, which included the five former officers, in the wake of Nichols' death. His family plans to hold a funeral for him on Wednesday, and a heartwarming video of Nichols showing his passion for skateboarding has gone viral as people share uplifting moments from his life. |
|
|
The skyrocketing popularity of the Type 2 diabetes medication Ozempic has led to a side effect called "Ozempic face" coined by a New York City cosmetic dermatologist who said he now sees it "every day" in patients. "Ozempic face" refers to a loss of facial fat that can leave the face sagging and looking older, particularly in middle-aged or older patients. It's a common side effect that many people who lose a significant amount of weight experience, doctors say. A woman who lost 68 pounds on the medication described getting "a gauntness" to her face, primarily in her lower jaw. Here's what to know about the drug, and what it's like to take Ozempic and Wegovy, another diabetes medication that's become popular for weight loss. |
|
|
Achieve your life goals with easy tips. |
|
|
Allow us to do the meal-planning for you. |
|
|
A little pick-me-up before you go. |
|
|
Thanks for letting us in your inbox! See you again tomorrow morning. |
Written by Scott Stump | Edited by Philip Caulfield Want to refer a friend? Subscribe here |
|
|
30 Rockefeller Plaza New York, NY 10112 |
|
|
|
0 comments